Pipeline and Commercial Insight: Insomnia - Future of Innovative Orexin Drug Class in Doubt by Datamonitor Now Available at ReportsandReports
The availability of generic versions of Ambien (zolpidem, Sanofi-Aventis) in the US from April 2007 onwards has intensified competition for both existing and prospective players in the insomnia market.
Dallas, TX, August 13, 2010 --(PR.com)-- ReportsandReports Announce it Will Carry Pipeline and Commercial Insight: Insomnia - Future of innovative orexin drug class in doubt Market Research Report in its Store.
Browse the complete Report on: http://www.reportsandreports.com/market-reports/pipeline-and-commercial-insight-insomnia-future-of-innovative-/
The availability of generic versions of Ambien (zolpidem, Sanofi-Aventis) in the US from April 2007 onwards has intensified competition for both existing and prospective players in the insomnia market. Following the discontinuation of three 5-HT antagonists in late-stage development over 20092010, orexin receptor antagonists now represent the most innovative candidates in the insomnia pipeline.
Scope
- Analysis of insomnia epidemiology, drug recommendations, patient acquisition process and unmet medical needs.
- In depth analysis of historic (200509) and future (201019) seven major market prescription sales dynamics.
- Review of prescription sales data in the Rest of World (200509) and analysis of insomnia epidemiology in Brazil and China.
- Commercial and clinical assessment of key late-stage pipeline drugs, with key opinion leader comment and country-specific sales forecasts to 2019.
Highlights
In 2019, the value of the seven major insomnia market is forecast to reach $3.5 billion. While growth of the US market is set to be inhibited by further generic erosion from 2011 onwards, Japan will represent the key growth region over the next 10 years.
Sanofi-Aventis's dominance in the insomnia market is under threat due to patent challenges to Ambien CR and Datamonitor expects generic versions of this market leading brand to enter the US over the forecast period. In the absence of pipeline insomnia candidates, Sanofi-Aventis is not expected to regain its market leading status.
Browse all Healthcare at http://www.reportsandreports.com/market-research/healthcare/
Browse all Datamonitor at http://www.reportsandreports.com/Publishers/datamonitor
Browse Latest Reports at: http://www.reportsandreports.com/LatestReport.aspx
Related Reports:
Pipeline Insight: Inflammatory Bowel Disease - Varied drug targets to broaden future therapy options
http://www.reportsandreports.com/market-reports/pipeline-insight-inflammatory-bowel-disease-varied-drug-target/
Pipeline Insight: Multiple Sclerosis - Risk-benefit ratio under the spotlight for potent pipeline drugs
http://www.reportsandreports.com/market-reports/pipeline-insight-multiple-sclerosis-risk-benefit-ratio-under-t/
Pipeline Insight: Osteoporosis - Bone building drugs become the heart of the pipeline
http://www.reportsandreports.com/market-reports/pipeline-insight-osteoporosis-bone-building-drugs-become-the-h/
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
http://www.reportsandreports.com/
http://reportsnreports.wordpress.com/
###
Browse the complete Report on: http://www.reportsandreports.com/market-reports/pipeline-and-commercial-insight-insomnia-future-of-innovative-/
The availability of generic versions of Ambien (zolpidem, Sanofi-Aventis) in the US from April 2007 onwards has intensified competition for both existing and prospective players in the insomnia market. Following the discontinuation of three 5-HT antagonists in late-stage development over 20092010, orexin receptor antagonists now represent the most innovative candidates in the insomnia pipeline.
Scope
- Analysis of insomnia epidemiology, drug recommendations, patient acquisition process and unmet medical needs.
- In depth analysis of historic (200509) and future (201019) seven major market prescription sales dynamics.
- Review of prescription sales data in the Rest of World (200509) and analysis of insomnia epidemiology in Brazil and China.
- Commercial and clinical assessment of key late-stage pipeline drugs, with key opinion leader comment and country-specific sales forecasts to 2019.
Highlights
In 2019, the value of the seven major insomnia market is forecast to reach $3.5 billion. While growth of the US market is set to be inhibited by further generic erosion from 2011 onwards, Japan will represent the key growth region over the next 10 years.
Sanofi-Aventis's dominance in the insomnia market is under threat due to patent challenges to Ambien CR and Datamonitor expects generic versions of this market leading brand to enter the US over the forecast period. In the absence of pipeline insomnia candidates, Sanofi-Aventis is not expected to regain its market leading status.
Browse all Healthcare at http://www.reportsandreports.com/market-research/healthcare/
Browse all Datamonitor at http://www.reportsandreports.com/Publishers/datamonitor
Browse Latest Reports at: http://www.reportsandreports.com/LatestReport.aspx
Related Reports:
Pipeline Insight: Inflammatory Bowel Disease - Varied drug targets to broaden future therapy options
http://www.reportsandreports.com/market-reports/pipeline-insight-inflammatory-bowel-disease-varied-drug-target/
Pipeline Insight: Multiple Sclerosis - Risk-benefit ratio under the spotlight for potent pipeline drugs
http://www.reportsandreports.com/market-reports/pipeline-insight-multiple-sclerosis-risk-benefit-ratio-under-t/
Pipeline Insight: Osteoporosis - Bone building drugs become the heart of the pipeline
http://www.reportsandreports.com/market-reports/pipeline-insight-osteoporosis-bone-building-drugs-become-the-h/
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
http://www.reportsandreports.com/
http://reportsnreports.wordpress.com/
###
Contact
ReportsandReports
Akshata Patil
+1-888-989-8004
http://www.reportsandreports.com/
Akshata Patil
+1-888-989-8004
http://www.reportsandreports.com/
Contact
Categories